The FinancialContent Network     SocialPicks Community   |   MarketMinute Monitor   |   MarketMinute Market Updates   |   MarketMinute Stock News
SocialPicks
   Sign Up   |   Log In   |   What is SocialPicks?     

Keryx Pharmaceuticals: Time to Buy Back In

 Oct 04, 2009 11:26 AM UTC
Return Risk
-11.17% HIGH
Tracked Blogger
Symbol Sentiment Start Return Closed
KERX n/a

Graphic_arrow1 Via Long Investment Ideas from Seeking Alpha:  

When shares of Keryx Biopharmaceuticals (KERX) spiked to over three dollars on Tuesday after the company issued a press release regarding the continued "impressive" efficacy of its treatment for Advanced Metastatic Renal Cell Carcinoma, Perifosine, I stated that it was a good time to take some profits after the recent, short-term triple in price. Now that the stock has quickly declined back to the two dollar range, it's time to buy back in and accumulate for the long term.

Keryx is loaded with potential, especially now that both of the company's product candidates, Zerenex and the aforementioned Perifisone, have been proven successful in Phase II trials. Phase III trials are now pending, according to the company's website. For those that may be new to the Keryx game, Zerenex is a treatment for developing kidney disease and Perifisone treats Advanced Metastatic Renal Cell Carcinoma.


 Graphic_website1 Read the rest of original post »



Add Comment

Be the first to comment on this story and earn 2 points.

Your Comment



IN THE PRESS
Press_forbes Press_washingtonpost Press_wsj Press_npr Press_techcrunch